“Antibody-drug conjugate (ADCs) in combination with immunotherapy is emerging as a promising strategy. However, concerns arise regarding the safety.
In this work, we present a combined analysis evaluating the safety and efficacy of this combination.”
Authors: Pablo Cresta Morgado, Lorenzo Carità, Victor Navarro, Tomas Pascual and Rodrigo Dienstmann.
